Key facts
- Eli Lilly shares rose 4% premarket following positive late-stage trial results for its obesity drug, retatrutide.
- The 4mg dose of retatrutide demonstrated approximately 19% weight loss, comparable to current blockbuster therapies.
- Analysts view the data as extending Eli Lilly's leadership in the obesity market.
- Side effects increased at higher doses of retatrutide, though tolerability was broadly in line with existing treatments.
- Eli Lilly's obesity portfolio depth was highlighted as a competitive advantage.
Eli Lilly shares jumped 4% in premarket trading on Monday after the company presented compelling new data for its next-generation obesity drug, retatrutide, at the American Diabetes Association meeting. Investors and analysts anticipate the drug will further solidify Lilly's leading position in the rapidly growing weight-loss market.
The most encouraging results came from the 4 mg dose of retatrutide, which achieved approximately 19% weight loss, a figure comparable to the highest dose of current market leader Zepbound. Tolerability was generally consistent, with similar rates of treatment discontinuation and relatively low instances of vomiting, although side effects did increase at higher doses.
Analysts from Citi noted that the efficacy of the 4mg dose is strong enough to warrant consideration for first-line treatment, positioning it as a subsequent option for patients who have already utilized Lilly's tirzepatide. The competitive landscape in the obesity market is increasingly focused on balancing efficacy with fewer side effects and simpler administration.
Eli Lilly's stock has gained 5.2% year-to-date, following a substantial rally in the previous year. In contrast, its primary competitor, Novo Nordisk, has experienced a roughly 15% decline year-to-date. J.P. Morgan analyst Chris Schott stated that Lilly possesses the necessary components to elevate the standard of care in obesity treatment and extend its long-term leadership in the over $200 billion incretin/obesity market.
Lilly also shared additional data on other candidates, including an approved weight-loss pill and another experimental injectable, eloralintide. RBC Capital Markets analyst Trung Huynh commented that the breadth of Lilly's obesity pipeline underscores its growing leadership and widening gap with competitors.